Javascript must be enabled to continue!
Segmentectomies in patients with primary malignant lung tumors
View through CrossRef
Objective. To study the immediate and long-term outcomes of segmentectomy and lobectomy for malignant lung tumors. Material and methods. A retrospective study included patients with primary malignant lung tumors who underwent anatomical lung resection, including segmentectomy (335 patients) and lobectomy (1.238 patients) via thoracoscopic and open approaches between January 01, 2009 and December 31, 2022. Patients who required conversion to thoracotomy were included in the open surgery group. We enrolled 240 patients for analysis (120 after segmentectomy for non-small cell lung cancer (NSCLC) and 120 after lobectomy for NSCLC, ratio 1:1). Results. The total number of complications in thoracoscopic segmentectomies differed from lobectomy (4.2% and 9%, respectively; p=0.047). The same trend was observed for open segmentectomies and lobectomies (4.8% and 9.6%, respectively; p=0.05). Recovery of external respiratory function occurred significantly faster after thoracoscopic segmentectomies compared to thoracoscopic lobectomies. Thus, preoperative forced expiratory volumes in 1 second (FEV1) were 85% (42–120) and 89% (80–97), respectively. After 6 months and 1 year, FEV1 after thoracoscopic segmentectomy reached 80% (40–111) and 84% (42–116), after thoracoscopic lobectomy — 80% (70–90) and 82% (72–94), respectively. The same trend was observed in groups of open segmentectomy and lobectomies. Preoperative FEV1 was 79% (39–125) and 90% (43–136), after 6 months — 75% (36–117) and 82% (36–121), after 1 year — 78% (37–123) and 83% (39–130), respectively. The overall 5-year survival rates for patients with stage Ia1 and Ia2 NSCLC after thoracoscopic segmentectomy and lobectomy were 90.4% and 91.5% (p=0.940), 5-year disease-free survival rates — 83.3% and 89.4%, respectively (p=0.949). The overall 5-year survival rates for patients with stage Ia1 and Ia2 NSCLC after open segmentectomy and lobectomy were 79.7% and 83.5% (p=0.951), 5-year disease-free survival rates — 74.5% and 76.9%, respectively (p=0.457). Conclusion. Segmentectomy is associated with lower complication rate than lobectomy, and long-term outcomes are comparable to those of lobectomy in patients with NSCLC <2 cm.
Media Sphere Publishing House
Title: Segmentectomies in patients with primary malignant lung tumors
Description:
Objective.
To study the immediate and long-term outcomes of segmentectomy and lobectomy for malignant lung tumors.
Material and methods.
A retrospective study included patients with primary malignant lung tumors who underwent anatomical lung resection, including segmentectomy (335 patients) and lobectomy (1.
238 patients) via thoracoscopic and open approaches between January 01, 2009 and December 31, 2022.
Patients who required conversion to thoracotomy were included in the open surgery group.
We enrolled 240 patients for analysis (120 after segmentectomy for non-small cell lung cancer (NSCLC) and 120 after lobectomy for NSCLC, ratio 1:1).
Results.
The total number of complications in thoracoscopic segmentectomies differed from lobectomy (4.
2% and 9%, respectively; p=0.
047).
The same trend was observed for open segmentectomies and lobectomies (4.
8% and 9.
6%, respectively; p=0.
05).
Recovery of external respiratory function occurred significantly faster after thoracoscopic segmentectomies compared to thoracoscopic lobectomies.
Thus, preoperative forced expiratory volumes in 1 second (FEV1) were 85% (42–120) and 89% (80–97), respectively.
After 6 months and 1 year, FEV1 after thoracoscopic segmentectomy reached 80% (40–111) and 84% (42–116), after thoracoscopic lobectomy — 80% (70–90) and 82% (72–94), respectively.
The same trend was observed in groups of open segmentectomy and lobectomies.
Preoperative FEV1 was 79% (39–125) and 90% (43–136), after 6 months — 75% (36–117) and 82% (36–121), after 1 year — 78% (37–123) and 83% (39–130), respectively.
The overall 5-year survival rates for patients with stage Ia1 and Ia2 NSCLC after thoracoscopic segmentectomy and lobectomy were 90.
4% and 91.
5% (p=0.
940), 5-year disease-free survival rates — 83.
3% and 89.
4%, respectively (p=0.
949).
The overall 5-year survival rates for patients with stage Ia1 and Ia2 NSCLC after open segmentectomy and lobectomy were 79.
7% and 83.
5% (p=0.
951), 5-year disease-free survival rates — 74.
5% and 76.
9%, respectively (p=0.
457).
Conclusion.
Segmentectomy is associated with lower complication rate than lobectomy, and long-term outcomes are comparable to those of lobectomy in patients with NSCLC <2 cm.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract
Introduction
Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Segmentectomy quality remains important in ground‐glass‐dominant stage I lung cancer
Segmentectomy quality remains important in ground‐glass‐dominant stage I lung cancer
AbstractBackgroundSegmentectomy for early‐stage lung cancer has benefits for survival and parenchymal preservation. However, segmentectomies are technically challenging, thereby re...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract
Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Carcinoma ex Pleomorphic Adenoma: A Case Series and Literature Review
Abstract
Introduction
Carcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor that can lead to severe complications and carries a risk of distant metastasi...

